U.S. flag

An official website of the United States government

GTR Home > Tests > Fanconi Anemia NGS Panel

Laboratory contact

Laboratory information


Fulgent Genetics, FLGT
Fulgent Genetics

Laboratory director(s)

  • Hanlin (Harry) Gao, PhD, ABMGG Board Certified, FACMG, Diplomate of the American Board of, Lab Director

Laboratory contact

  • Clinical Diagnostics Lab
  • 4399 Santa Anita Ave.
  • El Monte, California 91731
  • United States

Laboratory services offered

  • Clinical Testing/Confirmation of Mutations Identified Previously
  • Confirmation of research findings
  • Custom Deletion/Duplication Testing
  • Custom Prenatal Testing
  • Custom Sequence Analysis
  • Custom mutation-specific/Carrier testing
  • Insurance preauthorization
  • Insurance preverification
  • Maternal cell contamination study (MCC)
  • Mutation Confirmation
  • Somatic Sequence Analysis
  • Whole Exome Sequencing
  • Whole Genome Sequencing
  • X-Chromosome Inactivation Studies

Laboratory participation in external programs

Locus-specific Databases

Laboratory credentials

CLIA certification

  • Number: 05D2043189, Expiration: 2023-10-22

State license(s)

  • MD - Maryland Department of Health and Mental Hygiene DHMH, License number: 2250, Effective: 2020-07-09, Non-expiring
  • CA - California Department of Public Health CDPH, License number: CLF00342581, Expiration: 2023-12-29
  • NY - New York State Department of Health NYSDOH, License number: PFI: 9283, Expiration: 2024-06-30
  • PA - Pennsylvania Department of Health PADOH, License number: 33901, Expiration: 2024-08-15
  • RI - State of Rhode Island Department of Health RIDOH, License number: LCO01296, Expiration: 2024-12-30


  • CAP, Number: 8042697, Expiration: 2023-08-16
  • ISO15189, Number: 6359.01, Expiration: 2025-04-30

Suggested reading

  • USPSTF, 2019
    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force
  • USPSTF, 2013
    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation (See 2019 Update)
  • NCI PDQ, Breast and Gynecologic Cancers
    Genetics of Breast and Gynecologic Cancers (PDQ®): Health Professional Version
  • NCI PDQ, Cancer Genetics Counseling
    Cancer Genetics Risk Assessment and Counseling (PDQ®): Health Professional Version

Practice guidelines

  • NCCN, 2023
    Breast Cancer, NCCN Guidelines Version 4.2022
  • NCCN, 2022
    NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022
  • NICE, 2019
    UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2019
  • ACMG ACT, 2019
    American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.